News Industry alarm as FDA's CBER head Peter Marks resigns Industry organisations are alarmed by the resignation of senior FDA official Peter Marks, citing "misinformation and lies" by HHS Secretary Kennedy.
News Lilly to appeal after CHMP rejects Alzheimer's drug Kisunla The CHMP has advised against EU approval of Eli Lilly's Alzheimer's drug Kisunla, potentially handing an advantage to Eisai/Biogen's rival drug.
News HHS plans 10,000 more job cuts, taking target to 20,000 HHS Secretary Kennedy has said he intends to save $1.8bn per year, thanks to another wave of job cuts affecting the FDA, CDC, NIH, and CMS.
News BIO rings alarm bells over Trump's pharma tariffs US tariffs on goods coming from Europe, China, and Canada could have a major impact on the biopharma industry and medicines access, says BIO.
News FDA clears first treatment for Prader-Willi syndrome Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for excessive eating in rare disorder Prader-Willi syndrome.
News GSK ends decades-long hiatus in oral antibiotics for UTIs The FDA has approved GSK's Blujepa, the first new-mechanism oral antibiotic for uncomplicated UTIs in nearly 30 years, after a priority review.
R&D Immune mediation, B-cell depletion, and female leadership – ... In a new pharmaphorum podcast, Aoife Brennan, CEO of Climb Bio, discusses the treatment of immune-mediated diseases.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face